Show Transcript
NARRATOR:
What is BENLYSTA?
BENLYSTA is a prescription medicine used to treat people 5 years of age and older with active systemic lupus erythematosus (SLE or lupus) or active lupus nephritis (LN) (lupus-related kidney inflammation) who are receiving other lupus medicines. It is not known if BENLYSTA is safe and effective in people with severe active central nervous system lupus.
It is not known if BENLYSTA, given under the skin, is safe and effective in:
- children with SLE under 5 years of age or weighing less than 33 lbs
- children with LN under 18 years of age
It is not known if BENLYSTA, given in a vein (intravenously), is safe and effective in children less than 5 years of age.
Important Safety Information
Do not use BENLYSTA if you are allergic to belimumab or any ingredients in BENLYSTA.
Please click the Important Safety Information tab to the left to watch or hear the Important Safety Information about BENLYSTA.
ON-SCREEN TEXT:
Video will start in __ [countdown based on timing of previous and current read]
What is BENLYSTA?
BENLYSTA is a prescription medicine used to treat people 5 years of age and older with active systemic lupus erythematosus (SLE or lupus) or active lupus nephritis (LN) (lupus-related kidney inflammation) who are receiving other lupus medicines. It is not known if BENLYSTA is safe/effective in people with severe active central nervous system lupus.
It is not known if BENLYSTA, given under the skin, is safe/effective in:
- children with SLE under 5 years of age or weighing less than 33 lbs
- children with LN under 18 years of age
It is not known if BENLYSTA, given in a vein (intravenously), is safe and effective in children less than 5 years of age.
Important Safety Information
Do not use BENLYSTA if you are allergic to belimumab or any ingredients in BENLYSTA.
Please click the Important Safety Information tab to the left to watch or hear the Important Safety Information about BENLYSTA.
Benlysta
(belimumab)
ON-SCREEN TEXT:
Benlysta
(belimumab)
Intravenous Use 120 mg/vial
Subcutaneous Use 200 mg/mL
The Infusion Experience
SUSAN:
Of course, I was a little apprehensive at my first infusion, …
ON-SCREEN TEXT:
Susan
Real patient compensated by GSK. Receiving BENLYSTA at the time of filming. Individual results may vary.
SUSAN:
… but I had done my homework, so my biggest concern was if …
ON-SCREEN TEXT:
BENLYSTA (belimumab) can be given by intravenous (IV) infusion, which typically takes place in your doctor’s office, at a hospital, or at an infusion center.
SUSAN:
… they’d be able to get my vein right away. Thankfully, they did.
ON-SCREEN TEXT:
It takes about 1 hour to give you the full dose of BENLYSTA (belimumab). Preparation time before and observation time after the infusion may vary.
ON-SCREEN TEXT:
A healthcare professional will watch you closely while you are receiving BENLYSTA (belimumab) and after your infusion for signs of a reaction.
MICHELLE:
Before they start the infusion, …
ON-SCREEN TEXT:
Michelle
Real patient compensated by GSK. Receiving BENLYSTA at the time of filming.
MICHELLE:
… they’ll take your vitals and weight so they can calculate the right dosage just for you. Once they have the medicine ready, they will prep your arm and choose a vein.
MICHELLE:
I know for me, the very first infusion, it was definitely a little nerve-wracking. … The nurses walked me through everything, reassured me that they were there, every step of the way.
ON-SCREEN TEXT:
Michelle
MICHELLE:
And I remember just looking up at that infusion bag and saying: …
MICHELLE:
… “Well, this is it—I really hope this helps.”
ON-SCREEN TEXT:
Michelle
Individual results may vary.
Serious allergic reactions can happen on the day of, or in the days after, receiving BENLYSTA and may cause death.
SUSAN:
I think sitting in the chair, …
ON-SCREEN TEXT:
Susan
SUSAN:
… when I started to receive my infusion for the first time, …
ON-SCREEN TEXT:
Your healthcare professional may give you medicines before you receive BENLYSTA (belimumab) to help reduce your chance of having a reaction.
SUSAN:
… I was just—I was actually hopeful.
ON-SCREEN TEXT:
It is not known if these medications will help reduce the chance of an allergic reaction to BENLYSTA (belimumab). Individual results may vary.
SUSAN:
I just had this incredible sense of hope that this might be …
ON-SCREEN TEXT:
Some premedications may cause drowsiness. If you feel drowsy, have someone drive you home.
SUSAN:
… the drug that would help me.
MORGAN:
During my first BENLYSTA infusion, …
ON-SCREEN TEXT:
Morgan
Real patient compensated by GSK. Receiving BENLYSTA at the time of filming.
MORGAN:
… I was certainly nervous. I remember it being …
MORGAN:
… cold and quiet in the infusion clinic. My mother was there with me—she’s always there helping me and coming along for the ride. Those poor nurses—I never stopped talking.
ON-SCREEN TEXT:
Morgan
MICHELLE:
The best thing is to think about this, as you know, an hour, an hour and a half of time, just for yourself.
MICHELLE:
If you like to read, bring a book. If you’re someone who likes to knit or do things like that, bring something that is, you know, something you can do on your time. This is about you.
ON-SCREEN TEXT:
Michelle
MORGAN:
During my BENLYSTA infusions—it usually takes around an hour—and this time is usually spent for me. It’s my time. It’s my time to sit and reflect on things that are happening in my life.
ON-SCREEN TEXT:
Morgan
MORGAN:
During my BENLYSTA infusions, I typically have snacks—of course, cuz you know, you sit there for long enough—and books to read. Obviously, I have—I like to chat. There’s a lot of other patients around usually in the clinic, so I’m able to converse with them. And that helps to pass that time.
ON-SCREEN TEXT:
It takes about an hour to receive an infusion of BENLYSTA (belimumab). Preparation time and observation time may vary.
NARRATOR:
And now, Important Safety Information about BENLYSTA.
ON-SCREEN TEXT:
Benlysta
(belimumab)
Intravenous Use 120 mg/vial
Subcutaneous Use 200 mg/mL
Important Safety Information
NARRATOR:
What is BENLYSTA?
BENLYSTA is a prescription medicine used to treat people 5 years of age and older with active systemic lupus erythematosus (SLE or lupus) or active lupus nephritis (LN) (lupus-related kidney inflammation) who are receiving other lupus medicines. It is not known if BENLYSTA is safe and effective in people with severe active central nervous system lupus.
It is not known if BENLYSTA, given under the skin, is safe and effective in:
- children with SLE under 5 years of age or weighing less than 33 lbs
- children with LN under 18 years of age
It is not known if BENLYSTA, given in a vein (intravenously), is safe and effective in children less than 5 years of age.
Important Safety Information
Do not use BENLYSTA if you are allergic to belimumab or any ingredients in BENLYSTA.
ON-SCREEN TEXT:
What is BENLYSTA?
BENLYSTA is a prescription medicine used to treat people 5 years of age and older with active systemic lupus erythematosus (SLE or lupus) or active lupus nephritis (LN) (lupus-related kidney inflammation) who are receiving other lupus medicines. It is not known if BENLYSTA is safe/effective in people with severe active central nervous system lupus.
It is not known if BENLYSTA, given under the skin, is safe/effective in:
- children with SLE under 5 years of age or weighing less than 33 lbs
- children with LN under 18 years of age
It is not known if BENLYSTA, given in a vein (intravenously), is safe and effective in children less than 5 years of age.
Important Safety Information
Do not use BENLYSTA if you are allergic to belimumab or any ingredients in BENLYSTA.
Benlysta
(belimumab)
NARRATOR:
The most important information about BENLYSTA
Immunosuppressive agents, including BENLYSTA, can cause serious side effects. Some of these may cause death.
ON-SCREEN TEXT:
The most important information about BENLYSTA
Immunosuppressive agents, including BENLYSTA, can cause serious side effects. Some of these may cause death.
Benlysta
(belimumab)
NARRATOR:
Infections: fever, chills, pain or burning with urination, urinating often, coughing up mucus, or warm, red, or painful skin or sores on your body. Infections could be serious, leading to hospitalization or death.
ON-SCREEN TEXT:
The most important information about BENLYSTA
- Infections: fever, chills, pain or burning with urination, urinating often, coughing up mucus, or warm, red, or painful skin or sores on your body. Infections could be serious, leading to hospitalization or death.
Benlysta
(belimumab)
NARRATOR:
Allergic (hypersensitivity) reactions: itching, swelling of the face, lips, mouth, tongue, or throat, trouble breathing, anxiousness, low blood pressure, dizziness or fainting, headache, nausea, or skin rash. Serious allergic reactions can happen the day of, or in days after, receiving BENLYSTA and may cause death.
ON-SCREEN TEXT:
The most important information about BENLYSTA
- Allergic (hypersensitivity) reactions: itching, swelling of the face, lips, mouth, tongue, or throat, trouble breathing, anxiousness, low blood pressure, dizziness or fainting, headache, nausea, or skin rash. Serious allergic reactions can happen the day of, or in days after, receiving BENLYSTA and may cause death.
Benlysta
(belimumab)
NARRATOR:
Mental health problems and suicide: thoughts of suicide or dying, attempt to commit suicide, trouble sleeping (insomnia), new or worse anxiety or depression, acting on dangerous impulses, other unusual changes in your behavior or mood, or thoughts of hurting yourself or others.
ON-SCREEN TEXT:
The most important information about BENLYSTA
- Mental health problems and suicide: thoughts of suicide or dying, attempt to commit suicide, trouble sleeping (insomnia), new or worse anxiety or depression, acting on dangerous impulses, other unusual changes in your behavior or mood, or thoughts of hurting yourself or others.
Benlysta
(belimumab)
NARRATOR:
Before receiving BENLYSTA, discuss with your healthcare provider if you:
Think you have an infection or have infections that keep coming back. Do not use BENLYSTA if you have an infection unless your healthcare provider tells you to.
ON-SCREEN TEXT:
Before receiving BENLYSTA, discuss with your healthcare provider if you:
- think you have an infection or have infections that keep coming back. Do not use BENLYSTA if you have an infection unless your healthcare provider tells you to.
Benlysta
(belimumab)
NARRATOR:
Have or have had mental health problems such as depression or thoughts of suicide.
ON-SCREEN TEXT:
Before receiving BENLYSTA, discuss with your healthcare provider if you:
- have or have had mental health problems such as depression or thoughts of suicide.
Benlysta
(belimumab)
NARRATOR:
Have recently received or may need a vaccination. If you are receiving BENLYSTA, you should not receive live vaccines.
ON-SCREEN TEXT:
Before receiving BENLYSTA, discuss with your healthcare provider if you:
- have recently received or may need a vaccination. If you are receiving BENLYSTA, you should not receive live vaccines.
Benlysta
(belimumab)
NARRATOR:
Are taking any medicines, including prescription, over-the-counter, vitamins, and herbal supplements.
ON-SCREEN TEXT:
Before receiving BENLYSTA, discuss with your healthcare provider if you:
- are taking any medicines, including prescription, over-the-counter, vitamins, and herbal supplements.
Benlysta
(belimumab)
NARRATOR:
Are allergic to other medicines.
ON-SCREEN TEXT:
Before receiving BENLYSTA, discuss with your healthcare provider if you:
- are allergic to other medicines.
Benlysta
(belimumab)
NARRATOR:
Are receiving other biologic medicines.
ON-SCREEN TEXT:
Before receiving BENLYSTA, discuss with your healthcare provider if you:
- are receiving other biologic medicines.
Benlysta
(belimumab)
NARRATOR:
Have or have had any type of cancer.
ON-SCREEN TEXT:
Before receiving BENLYSTA, discuss with your healthcare provider if you:
- have or have had any type of cancer.
Benlysta
(belimumab)
NARRATOR:
Have any other medical conditions.
ON-SCREEN TEXT:
Before receiving BENLYSTA, discuss with your healthcare provider if you:
- have any other medical conditions.
Benlysta
(belimumab)
NARRATOR:
Are pregnant or plan to become pregnant. It is unknown if BENLYSTA will harm your unborn baby. Talk to your healthcare provider about whether to prevent pregnancy while on BENLYSTA. If you choose to prevent pregnancy, you should use an effective method of birth control for at least 4 months after the final dose of BENLYSTA.
ON-SCREEN TEXT:
Before receiving BENLYSTA, discuss with your healthcare provider if you:
- are pregnant or plan to become pregnant. It is unknown if BENLYSTA will harm your unborn baby. Talk to your healthcare provider about whether to prevent pregnancy while on BENLYSTA. If you choose to prevent pregnancy, you should use an effective method of birth control for at least 4 months after the final dose of BENLYSTA.
Benlysta
(belimumab)
NARRATOR:
Become pregnant while receiving BENLYSTA, talk to your healthcare provider about enrolling in the BENLYSTA Pregnancy Registry. You can enroll in this registry by calling 1-877-311-8972 or go to mothertobaby.org/ongoing-study/benlysta-belimumab/.
ON-SCREEN TEXT:
Before receiving BENLYSTA, discuss with your healthcare provider if you:
Benlysta
(belimumab)
NARRATOR:
Are breastfeeding or plan to breastfeed. It is unknown if BENLYSTA passes into your breast milk.
ON-SCREEN TEXT:
Before receiving BENLYSTA, discuss with your healthcare provider if you:
- are breastfeeding or plan to breastfeed. It is unknown if BENLYSTA passes into your breast milk.
Benlysta
(belimumab)
NARRATOR:
Possible side effects of BENLYSTA
Progressive multifocal leukoencephalopathy (PML). PML is a serious and life-threatening brain infection. PML can result in death or severe disability. Tell your healthcare provider right away if you notice any new or worsening medical problems: memory loss, trouble thinking, dizziness or loss of balance, difficulty talking or walking, or loss of vision.
ON-SCREEN TEXT:
Possible side effects of BENLYSTA
- Progressive multifocal leukoencephalopathy (PML). PML is a serious and life-threatening brain infection. PML can result in death or severe disability. Tell your healthcare provider right away if you notice any new or worsening medical problems: memory loss, trouble thinking, dizziness or loss of balance, difficulty talking or walking, or loss of vision.
Benlysta
(belimumab)
NARRATOR:
Cancer. Medicines that affect the immune system, including BENLYSTA, may increase your risk of certain cancers.
ON-SCREEN TEXT:
Possible side effects of BENLYSTA
- Cancer. Medicines that affect the immune system, including BENLYSTA, may increase your risk of certain cancers.
Benlysta
(belimumab)
NARRATOR:
The most common side effects of BENLYSTA are nausea, diarrhea, fever, stuffy or runny nose and sore throat, persistent cough, trouble sleeping, leg or arm pain, depression, headache, and pain, redness, itching, or swelling at the site of injection (when given subcutaneously). These are not all the possible side effects of BENLYSTA. Call your doctor for medical advice about side effects.
ON-SCREEN TEXT:
Possible side effects of BENLYSTA
The most common side effects of BENLYSTA are nausea, diarrhea, fever, stuffy or runny nose and sore throat, persistent cough, trouble sleeping, leg or arm pain, depression, headache, and pain, redness, itching, or swelling at the site of injection (when given subcutaneously). These are not all the possible side effects of BENLYSTA. Call your doctor for medical advice about side effects.
Benlysta
(belimumab)
ON-SCREEN TEXT:
For more information and access to Prescribing Information and Medication Guide, visit www.BENLYSTA.com or call BENLYSTA Gateway at 1-877-4-BENLYSTA (1-877-423-6597) Monday through Friday, 8 AM to 8 PM Eastern Time.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Benlysta Cares
Have questions or need assistance?
Call 1-877-4-BENLYSTA
(1-877-423-6597)
Personalized Support
Benefits & Savings
Exclusive Resources
Whether you are insured, underinsured, or uninsured, BENLYSTA Cares and our team at BENLYSTA Gateway may be able to help.
Benlysta
(belimumab)
GSK
Trademarks are owned by or licensed to the GSK group of companies.
©2024 GSK or licensor.
PMUS-BELVID240020 July 2024
Produced in USA.
close
